Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:07 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
An Exploratory Study to Investigate the Effect of FE 999302 When Given Together With Follitropin Delta During Controlled Ovarian Stimulation
NCT06466486 · Ferring Pharmaceuticals · PHASE1 · terminated · last registry update 2026-03-30 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “This is a company decision made not related to safety concerns. Rather, it reflects a broader portfolio assessment and the desire to focus on programs that can bring timely and meaningful benefit to patients.” | – | Registry record, Ferring Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against FSHR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-29Also stopped (withdrawn): American Hospital 2 Kosovo, Follicle-stimulating hormone (FSH) + Follicle-stimulating hormone (FSH) (NCT07346235)
- 2026-10-29Also stopped (withdrawn): Azienda Sanitaria Locale Bari, Follicle Stimulating Hormone (NCT02275169)
- 2026-10-13Also stopped (terminated): Universitair Ziekenhuis Brussel, a drug against FSHR (NCT03686852)
- 2026-09-11Phase 3 first posted: Fundación para la Investigación del Hospital Clínico de Valencia, Human chorionic gonadotropin (hCG) + Follitropin delta (NCT07816562)
- 2026-08-28Results posted on the registry: Ferring Pharmaceuticals, FE 999049 + Placebo (NCT05403476)
- 2026-08-28Also stopped (terminated): Ferring Pharmaceuticals, FE 999049 + Placebo (NCT05403476)
- 2026-03-30Also stopped (terminated): Ferring Pharmaceuticals, FE 999302 + Follitropin delta (NCT06511791)
- 2026-02-12Results posted on the registry: Ferring Pharmaceuticals, FE 999049 + GONAL-F (NCT06173869)
- 2026-01-16Phase 3 first posted: American Hospital 2 Kosovo, Follicle-stimulating hormone (FSH) + Follicle-stimulating hormone (FSH) (NCT07346235)
- 2026-01-14Phase 3 first posted: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, Follitropin alfa/lutropin alfa (MBJ-0011) + hMG (NCT07340827)
- 2025-12-09Results posted on the registry: Memorial Sloan Kettering Cancer Center, Vagifem® (vaginal 17β-estradiol) questionnaire & menopause symptom checklist (NCT00984399)
- 2025-10-15Phase 3 first posted: Granata Bio Corporation, hMG subcutaneous injection + Placebo (NCT07216742)
- 2025-07-11Results posted on the registry: NRG Oncology, Gonadotrophin Releasing Hormone + Niraparib (NCT04037254)
- 2025-05-18Results posted on the registry: Instituto Bernabeu, Corifollitropin Alfa + Follitropin Alfa (NCT05815719)
- 2025-04-02Results posted on the registry: Ferring Pharmaceuticals, REKOVELLE (Follitropin Delta) (NCT05263388)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision